| Name | Title | Contact Details |
|---|
Transgenomic is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is the global leader in cardiac genetic testing with a family of innovative products designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.
Aerolase designs, manufactures and markets the LightPod family of lasers, which represent a technology breakthrough in the field of laser medicine. The result is a new generation of aesthetic and dermatology lasers, built on the proven safety and versatility of gold-standard medical laser modalities. LightPod lasers deliver the highest power for aesthetic & dermatology treatments with uniquely optimized laser pulse parameters based on clinical research. They lead the industry with an unprecedented combination of Efficacy, Safety, Versatility, and Return on Investment.
Obbligato Objectives is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Claflin Company is a Warwick, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed`s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals in the clinical assessment of secondary lymphoedema of the arm in female breast cancer patients.